As of November 6, 2026, enVVeno Medical Corp is a publicly traded company (Nasdaq: NVNO). The largest holder reporting an active stake on Schedule 13D is Northstrive Fund II LP, at 5.05%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Thomas A. Satterfield, Jr. (9%), Kingdon Capital Management, L.L.C. (5.5%) (Schedule 13D, February 20, 2026).
Is this your company?
About to sign with, pay or invest in enVVeno Medical Corp? See the free Snapshot first.
Free to see. No signup.
Is enVVeno Medical Corp a real, registered company?
- enVVeno Medical Corp files with the SEC under CIK 1661053 (its SEC filings).
- Its shares are listed under the ticker NVNO on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Irvine, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under enVVeno Medical Corp in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Perceptive Advisors (filed 2026-05-15).
Who are enVVeno Medical Corp's owners and officers?
enVVeno Medical Corp: incorporated in Delaware; business address in Irvine, California; industry Surgical & Medical Instruments & Apparatus (Schedule 13D/A, 2026-09-15).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-09-15 | Braeden Lichti | 0% |
| Schedule 13G/A, 2026-08-14 | Perceptive Advisors LLC | 3.5% |
| Schedule 13G/A, 2026-05-15 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G/A, 2026-05-15 | Kingdon Capital Management, L.L.C. | 5.5% |
| Schedule 13D, 2026-02-20 | Northstrive Fund Ii LP | 5.05% |
| Schedule 13D, 2026-02-20 | Braeden Lichti | 5.05% |
| Schedule 13G/A, 2026-02-17 | Perceptive Advisors LLC | 9.99% |
| Schedule 13G, 2026-02-10 | Braeden Lichti | 5.05% |
| Schedule 13G, 2026-02-10 | Braeden Lichti | 5.05% |
| Schedule 13G, 2025-11-19 | Thomas A. Satterfield, Jr. | 9% |
| Schedule 13G/A, 2025-11-14 | Nantahala Capital Management, LLC | 3.46% |
| Schedule 13G, 2025-09-09 | Kingdon Capital Management, L.L.C. | 7.1% |
Questions about who owns enVVeno Medical Corp
Who owns enVVeno Medical Corp?
On this page, 3 holders' latest ownership filings report 5% or more of enVVeno Medical Corp: Thomas A. Satterfield, Jr. (9%, Schedule 13G, filed 2025-11-19), Kingdon Capital Management, L.L.C. (5.5%, Schedule 13G/A, filed 2026-05-15) and Northstrive Fund Ii LP (5.05%, Schedule 13D, filed 2026-02-20).
Who are the largest shareholders of enVVeno Medical Corp?
By the share each holder's latest filing reports, the largest holders of enVVeno Medical Corp on this page are Thomas A. Satterfield, Jr. (9%), Kingdon Capital Management, L.L.C. (5.5%) and Northstrive Fund Ii LP (5.05%).
When did Thomas A. Satterfield, Jr. buy into enVVeno Medical Corp?
The filings give report dates, not purchase dates. The earliest filing from Thomas A. Satterfield, Jr. on this page is the Schedule 13G, filed 2025-11-19, reporting 9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on enVVeno Medical Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on enVVeno Medical Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on enVVeno Medical Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
18 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own enVVeno Medical Corp shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 22,236 shares (3.2% of shares outstanding) (Form 4, 2025-12-18).
- , a director: 16,545 shares (2.4% of shares outstanding) (Form 4, 2024-12-23).
- , a director: 11,155 shares (1.6% of shares outstanding) (Form 4, 2025-01-02).
- , a director: 9,288 shares (1.3% of shares outstanding) (Form 4, 2024-12-26).
- , a director: 2,351 shares (0.34% of shares outstanding) (Form 4, 2026-09-14).
Shares outstanding: 694,826 as of 2026-10-27, from the company's latest SEC cover page.
How much has enVVeno Medical Corp raised?
No fundraising or offering filing from enVVeno Medical Corp is on file with us.
Keep reading
More on enVVeno Medical Corp and the records around it.
enVVeno Medical Corp elsewhere on the record
- 5%+ stake filings Sep 2026
Companies that share a holder
- Kingdon Capital Management, L.L.C. also filed stake reports on 2 other companies: SCYNEXIS INC (Feb 2026), Jasper Therapeutics, Inc. (Nov 2025)
- Northstrive Fund II LP also filed stake reports on 2 other companies: Bluejay Diagnostics, Inc. (Jun 2026), ENVERIC BIOSCIENCES, INC. (Dec 2025)
- Braeden Lichti also filed stake reports on 3 other companies: PMGC Holdings Inc. (Jun 2026), Bluejay Diagnostics, Inc. (Jun 2026), ENVERIC BIOSCIENCES, INC. (Dec 2025)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/envveno-medical